Preservation of cell-based immunotherapies for clinical trials

RUI Li, R Johnson, G Yu, DH McKenna, A Hubel - Cytotherapy, 2019 - Elsevier
In the unique supply chain of cellular therapies, preservation is important to keep the cell
product viable. Many factors in cryopreservation affect the outcome of a cell therapy:(i) …
被引用次数：83 相关文章

Preservation of cell-based immunotherapies for clinical trials

R Li, R Johnson, G Yu, DH McKenna… - …, 2019 - pubmed.ncbi.nlm.nih.gov
In the unique supply chain of cellular therapies, preservation is important to keep the cell
product viable. Many factors in cryopreservation affect the outcome of a cell therapy:(i) …

[引用][C] Preservation of cell-based immunotherapies for clinical trials

RUI LI, R JOHNSON, G YU, DH MCKENNA, A HUBEL - Cytotherapy, 2019 - cir.nii.ac.jp
Preservation of cell-based immunotherapies for clinical trials | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …

Preservation of cell-based immunotherapies for clinical trials.

R Li, R Johnson, G Yu, DH McKenna, A Hubel - Cytotherapy, 2019 - europepmc.org
In the unique supply chain of cellular therapies, preservation is important to keep the cell
product viable. Many factors in cryopreservation affect the outcome of a cell therapy: 1) …
[HTML] nih.gov

[HTML][HTML] Preservation of cell-based immunotherapies for clinical trials

R Li, R Johnson, G Yu, DH McKenna, A Hubel - Cytotherapy, 2019 - ncbi.nlm.nih.gov
In the unique supply chain of cellular therapies, preservation is important to keep the cell
product viable. Many factors in cryopreservation affect the outcome of a cell therapy: 1) …

Preservation of cell-based immunotherapies for clinical trials

R Li, R Johnson, G Yu, DH McKenna, A Hubel - Cytotherapy, 2019 - experts.umn.edu
In the unique supply chain of cellular therapies, preservation is important to keep the cell
product viable. Many factors in cryopreservation affect the outcome of a cell therapy:(i) …